Clinical characteristics of patients with MPNs with or without a CVRF, as divided by disease subtype
| . | All MPNs . | ET . | PV . | MF . | ||||
|---|---|---|---|---|---|---|---|---|
| No CVRF (n = 663) . | ≥1 CVRF (n = 342) . | No CVRF (n = 303) . | ≥1 CVRF (n = 112) . | No CVRF (n = 209) . | ≥1 CVRF (n = 104) . | No CVRF (n = 115) . | ≥1 CVRF (n = 100) . | |
| Female, n (%) | 365 (55) | 157 (46) | 184 (61) | 60 (54) | 112 (54) | 46 (44) | 53 (46) | 34 (34) |
| Age at MPN diagnosis, median (range), y | 56 (9-91) | 65 (18-96) | 53 (9-87) | 61 (18-96) | 54 (18-91) | 64 (21-94) | 63 (21-86) | 68 (31-84) |
| First MPN diagnosis, n (%) | ||||||||
| ET | 303 (46) | 112 (33) | ||||||
| PV | 209 (32) | 104 (30) | ||||||
| Pre-MF | 15 (2) | 13 (4) | ||||||
| MF | 115 (17) | 100 (29) | ||||||
| MPN NOS | 21 (3) | 13 (4) | ||||||
| Race, n (%) | ||||||||
| White | 609 (92) | 304 (89) | 278 (92) | 95 (85) | 192 (92) | 96 (92) | 106 (92) | 89 (89) |
| Black | 17 (3) | 14 (4) | 9 (3) | 7 (6) | 4 (2) | 4 (4) | 4 (3) | 3 (3) |
| Asian | 21 (3) | 8 (2) | 10 (3) | 5 (4) | 7 (3) | 1 (1) | 3 (3) | 2 (2) |
| Unknown | 16 (2) | 16 (5) | 6 (2) | 5 (4) | 6 (3) | 3 (3) | 2 (2) | 6 (6) |
| Median follow-up, y | 8.3 | 3.1 | 8.9 | 4.3 | 11.3 | 3.5 | 4 | 2.2 |
| Driver mutation | ||||||||
| JAK2 | 435 (66)∗ | 228 (67) | 166 (55)∗ | 56 (50) | 192 (92)∗ | 96 (92) | 59 (51)∗ | 61 (61) |
| CALR | 119 (18) | 49 (14) | 89 (29) | 28 (25) | 23 (20) | 20 (20) | ||
| MPL | 32 (5)∗ | 20 (6) | 14 (5)∗ | 10 (9) | 1 (0)∗ | 15 (13)∗ | 8 (8) | |
| Triple negative | 81 (12) | 45 (13) | 36 (12) | 18 (16) | 17 (8) | 8 (8) | 19 (17) | 11 (11) |
| VAF, median (range) | ||||||||
| JAK2 | 50.63 (0.45-99.41) | 37.61 (1.03-97.73) | 30.17 (0.45-96.69) | 24.39 (1.39-91.24) | 70.27 (1.98-99.41) | 40.31 (1.03-96.73) | 51.83 (1.65-97.62) | 44.16 (2.81-95.71) |
| CALR | 34.26 (2.52-89.39) | 34.35 (9.01-80.65) | 33.33 (2.52-61.22) | 31.20 (9.01-57.75) | 39.29 (22.78-82.35) | 36.37 (23.12-80.65) | ||
| MPL | 43.52 (2.75-93.06) | 38.09 (3.27-79.38) | 42.48 (2.75-93.06) | 18.05 (3.27-69.19) | 3.93 (3.93-3.93) | 53.23 (32.27-90.83) | 45.66 (32.30-75.37) | |
| Nondriver mutations | ||||||||
| Yes | 354 (53) | 187 (55) | 139 (46) | 35 (31) | 102 (49) | 60 (58) | 81 (70) | 75 (75) |
| Median (range) | 1 (0-6) | 1 (0-7) | 0 (0-6) | 0 (0-5) | 0 (0-6) | 1 (0-5) | 1 (0-6) | 1 (0-7) |
| BMI, median (range) | 24.82 (15.48-52.42) | 27.50 (15.33-58.10) | 24.64 (16.45-47.93) | 27.35 (15.33-58.10) | 24.94 (15.48-41.04) | 26.45 (20.04-47.37) | 24.41 (17.52-40.19) | 27.75 (18.68-54.91) |
| History of venous thrombosis, n (%) | 21 (3) | 21 (6) | 8 (3) | 9 (8) | 7 (3) | 4 (4) | 4 (4) | 6 (6) |
| History of arterial thrombosis, n (%) | 34 (5) | 56 (16) | 13 (4) | 18 (16) | 12 (6) | 19 (17) | 6 (5) | 13 (13) |
| . | All MPNs . | ET . | PV . | MF . | ||||
|---|---|---|---|---|---|---|---|---|
| No CVRF (n = 663) . | ≥1 CVRF (n = 342) . | No CVRF (n = 303) . | ≥1 CVRF (n = 112) . | No CVRF (n = 209) . | ≥1 CVRF (n = 104) . | No CVRF (n = 115) . | ≥1 CVRF (n = 100) . | |
| Female, n (%) | 365 (55) | 157 (46) | 184 (61) | 60 (54) | 112 (54) | 46 (44) | 53 (46) | 34 (34) |
| Age at MPN diagnosis, median (range), y | 56 (9-91) | 65 (18-96) | 53 (9-87) | 61 (18-96) | 54 (18-91) | 64 (21-94) | 63 (21-86) | 68 (31-84) |
| First MPN diagnosis, n (%) | ||||||||
| ET | 303 (46) | 112 (33) | ||||||
| PV | 209 (32) | 104 (30) | ||||||
| Pre-MF | 15 (2) | 13 (4) | ||||||
| MF | 115 (17) | 100 (29) | ||||||
| MPN NOS | 21 (3) | 13 (4) | ||||||
| Race, n (%) | ||||||||
| White | 609 (92) | 304 (89) | 278 (92) | 95 (85) | 192 (92) | 96 (92) | 106 (92) | 89 (89) |
| Black | 17 (3) | 14 (4) | 9 (3) | 7 (6) | 4 (2) | 4 (4) | 4 (3) | 3 (3) |
| Asian | 21 (3) | 8 (2) | 10 (3) | 5 (4) | 7 (3) | 1 (1) | 3 (3) | 2 (2) |
| Unknown | 16 (2) | 16 (5) | 6 (2) | 5 (4) | 6 (3) | 3 (3) | 2 (2) | 6 (6) |
| Median follow-up, y | 8.3 | 3.1 | 8.9 | 4.3 | 11.3 | 3.5 | 4 | 2.2 |
| Driver mutation | ||||||||
| JAK2 | 435 (66)∗ | 228 (67) | 166 (55)∗ | 56 (50) | 192 (92)∗ | 96 (92) | 59 (51)∗ | 61 (61) |
| CALR | 119 (18) | 49 (14) | 89 (29) | 28 (25) | 23 (20) | 20 (20) | ||
| MPL | 32 (5)∗ | 20 (6) | 14 (5)∗ | 10 (9) | 1 (0)∗ | 15 (13)∗ | 8 (8) | |
| Triple negative | 81 (12) | 45 (13) | 36 (12) | 18 (16) | 17 (8) | 8 (8) | 19 (17) | 11 (11) |
| VAF, median (range) | ||||||||
| JAK2 | 50.63 (0.45-99.41) | 37.61 (1.03-97.73) | 30.17 (0.45-96.69) | 24.39 (1.39-91.24) | 70.27 (1.98-99.41) | 40.31 (1.03-96.73) | 51.83 (1.65-97.62) | 44.16 (2.81-95.71) |
| CALR | 34.26 (2.52-89.39) | 34.35 (9.01-80.65) | 33.33 (2.52-61.22) | 31.20 (9.01-57.75) | 39.29 (22.78-82.35) | 36.37 (23.12-80.65) | ||
| MPL | 43.52 (2.75-93.06) | 38.09 (3.27-79.38) | 42.48 (2.75-93.06) | 18.05 (3.27-69.19) | 3.93 (3.93-3.93) | 53.23 (32.27-90.83) | 45.66 (32.30-75.37) | |
| Nondriver mutations | ||||||||
| Yes | 354 (53) | 187 (55) | 139 (46) | 35 (31) | 102 (49) | 60 (58) | 81 (70) | 75 (75) |
| Median (range) | 1 (0-6) | 1 (0-7) | 0 (0-6) | 0 (0-5) | 0 (0-6) | 1 (0-5) | 1 (0-6) | 1 (0-7) |
| BMI, median (range) | 24.82 (15.48-52.42) | 27.50 (15.33-58.10) | 24.64 (16.45-47.93) | 27.35 (15.33-58.10) | 24.94 (15.48-41.04) | 26.45 (20.04-47.37) | 24.41 (17.52-40.19) | 27.75 (18.68-54.91) |
| History of venous thrombosis, n (%) | 21 (3) | 21 (6) | 8 (3) | 9 (8) | 7 (3) | 4 (4) | 4 (4) | 6 (6) |
| History of arterial thrombosis, n (%) | 34 (5) | 56 (16) | 13 (4) | 18 (16) | 12 (6) | 19 (17) | 6 (5) | 13 (13) |
Boldface type indicates significant differences (P < .05).
NOS, not otherwise specified.
Four patients had a simultaneous mutation in JAK2 and MPL.